ADC Therapeutics' IFRS loss for 6 months of 2021 was $124.096 million, down 27% from $170.033 million in the prior year. Revenues were $3.76 million. A year earlier, the company did not generate revenues.
ADC Therapeutics' IFRS loss for 6 months of 2021 was $124.096 million, down 27% from $170.033 million in the prior year. Revenues were $3.76 million. A year earlier, the company did not generate revenues. 
ir.adctherapeutics.com
English (US) 